Decreased dynorphin levels and increased kappa opioid receptor binding in male rats with isolation-induced hypertension

Wright, Rebecca C; McConnaughey, Mona M.; Ingenito, Alphonse J.

doi:10.1016/s0196-9781(00)00331-4

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While KOR antagonists have been at the forefront of treatment options for psychiatric illnesses, they are also implicated in a medley of other physiological disorders, including salt consumption (Nascimento et al 2012), epilepsy and hypertension (though hypertension is not discussed here, see(Wright & Ingenito 2001, Wright & Ingenito 2003, Wright et al 2000) for further reading). This brings together the importance of the “whole body” perspective when considering KOR drugs as therapeutic treatment for brain-related diseases.…”

Section: Conclusion: Role Of Kors In Stress and Anxiety Potential Asmentioning

confidence: 99%

Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment

Crowley

Kash

2015

Progress in Neuro-Psychopharmacology and Biological Psychiatry

106

View full text Add to dashboard Cite

Kappa opioid receptors (KORs) in the central nervous system have been known to be important regulators of a variety of psychiatry illnesses, including anxiety and addiction, but their precise involvement in these behaviors is complex and has yet to be fully elucidated. Here, we briefly review the pharmacology of KORs in the brain, including KOR's involvement in anxiety, depression, and alcohol addiction. We also review the known neuronal circuitry impacted by KOR signaling, and interactions with corticotrophin-releasing factor (CRF), another key peptide in anxiety-related illnesses, as well as the role of glucocorticoids. We suggest that KORs are a promising therapeutic target for a host of neuropsychiatric conditions.

show abstract